Early intervention strategies to lower cardiovascular risk in early nephropathy: focus on dyslipidemia

Cardiology Clinics
Matthew J Sorrentino

Abstract

Patients with chronic kidney disease (CKD) are at high cardiovascular risk and we can consider them to have a risk equivalent to coronary heart disease, putting them into the high-risk category. A mixed dyslipidemia with high triglyceride levels; low high-density lipoprotein (HDL) levels; and small, dense low-density lipoprotein (LDL) particles is a common pattern in patients with CKD, contributing to their high cardiovascular disease (CVD) risk. A treatment strategy to reduce LDL cholesterol to the current high-risk category goals reduces risk similar to patients without CKD. Emerging evidence suggests that targeting non-HDL cholesterol can have the potential to bring about further CVD risk reduction. Non-HDL cholesterol should be a secondary target for all patients with CKD. Further studies are needed to determine the magnitude of the risk reduction we can expect to gain by targeting non-HDL cholesterol and the most effective way to treat this target.

References

Mar 1, 1988·Kidney International·B L KasiskeW F Keane
Oct 1, 1995·Hypertension·M MänttäriV Manninen
May 1, 1997·The American Journal of Clinical Nutrition·W S Harris
Nov 20, 1998·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·B L Kasiske
Jun 26, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·N D VaziriK Liang
Oct 31, 2000·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·K A KohlerJ R Boring
Jan 3, 2001·Kidney International·L F FriedB L Kasiske
Jan 4, 2001·The New England Journal of Medicine·F M SacksUNKNOWN DASH-Sodium Collaborative Research Group
May 23, 2001·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·S Vázquez-PérezV Cachofeiro
Jul 31, 2001·JAMA : the Journal of the American Medical Association·H C GersteinUNKNOWN HOPE Study Investigators
Mar 6, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Camille A JonesLawrence Y Agodoa
Apr 23, 2002·Kidney International·Kunitoshi IsekiShuichi Takishita
May 1, 2002·Current Opinion in Nephrology and Hypertension·Meena Sahadevan, Bertram L Kasiske
Oct 3, 2002·Circulation·Hans L HillegeUNKNOWN Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group
Mar 19, 2003·Seminars in Dialysis·Katrin UhligMark J Sarnak
May 23, 2003·Journal of the American Society of Nephrology : JASN·Marcello TonelliUNKNOWN Cholesterol and Recurrent Events Trial Investigators
Jul 23, 2003·Journal of the American Society of Nephrology : JASN·Elke S SchaeffnerJ Michael Gaziano
Sep 5, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Solfrid RomundstadHanne Ellekjaer
Nov 8, 2003·Hypertension·Mark J SarnakUNKNOWN American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology,
Jul 29, 2004·American Journal of Physiology. Renal Physiology·N D Vaziri, K Liang
Oct 20, 2004·Circulation·Folkert W AsselbergsUNKNOWN Prevention of Renal and Vascular Endstage Disease Intervention Trial (PREVEND IT) Investigators
Mar 10, 2005·The New England Journal of Medicine·John C LaRosaUNKNOWN Treating to New Targets (TNT) Investigators
Jan 13, 2006·American Journal of Physiology. Renal Physiology·N D Vaziri
Jan 31, 2006·Hemodialysis International·Nosratola D Vaziri, Hamid Moradi
Jun 10, 2006·Journal of the American Society of Nephrology : JASN·Sabrina SandhuMarcello Tonelli
Jul 19, 2006·Annals of Internal Medicine·Kevin DouglasJeffrey L Jackson
Mar 21, 2007·The American Journal of Cardiology·Michael H DavidsonTerry A Jacobson
Nov 21, 2007·Circulation·Scott D SolomonUNKNOWN Prevention of Events With ACE Inhibition (PEACE) Investigators
Jun 21, 2008·Journal of the American College of Cardiology·Charles R Harper, Terry A Jacobson
Feb 14, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Michael J KorenUNKNOWN ALLIANCE Investigators
Nov 26, 2009·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Lori D BashJosef Coresh

❮ Previous
Next ❯

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

Cardiovascular Inflammation

Inflammation plays a significant role in the development of cardiovascular diseases, an understanding of these endogenous processes is critical for evaluating the risks and potential treatment strategies. Discover the latest research on cardiovascular inflammation here.

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.